secwatch.observer — SEC 8-K summary
======================================

Issuer:     Quince Therapeutics, Inc. (QNCX)
CIK:        0001662774
Form:       8-K
Filed at:   2026-06-26T13:18:21+00:00
Accession:  0001193125-26-284089
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 3.03, 5.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Quince Therapeutics announces 1-for-20 reverse stock split effective June 29, 2026
--------------------------------------------------------------------------------

- Stockholders approved reverse split on June 11, 2026; board set ratio at 1-for-20.
- Certificate of Amendment filed with Delaware Secretary of State on June 26, 2026; effective June 29 at 11:59 pm ET.
- Pre-split shares outstanding: 19,559,257; post-split approx 977,963; CUSIP changes to 22053A305.
- Ticker remains QNCX; options and warrants proportionally adjusted; fractional shares cashed out.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1662774/000119312526284089/0001193125-26-284089-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1662774/000119312526284089/d168420d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-284089

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer